MannKind Corp. (NASDAQ: MNKD), a Danbury-based company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, has named Lauren Sabella as executive vice president and chief operating officer.
Prior to joining MannKind, she was at Acorda Therapeutics for 12 years, most recently as chief operating officer. Prior to that role, Sabella was Acorda”™s chief commercial officer and launched their flagship product Ampyra for multiple sclerosis. Earlier in her career, she was vice president of commercial development at Altus Pharmaceuticals, with responsibility for all aspects of commercialization.
“I am honored and excited to be joining MannKind as it continues to scale and execute its plan to help people living with endocrine and orphan lung diseases,” said Sabella. “I am energized to work with this innovative team as we drive operational excellence in an action-driven environment.”
